Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations - Takeaways - MDSpire

Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations

  • By

  • Ziyun Wang

  • Yijin Wang

  • Wangning Shangguan

  • Tao Li

  • June 9, 2026

  • 0 min

Share

  • 1

    SGLT2 inhibitors provide cardiovascular benefits beyond glycemic control, impacting heart failure and cardiorenal health.

  • 2

    Empagliflozin and dapagliflozin show significant prognostic benefits in heart failure with reduced and preserved ejection fraction.

  • 3

    The mechanisms of SGLT2 inhibitors include hemodynamic rebalancing, vascular protection, and metabolic reprogramming.

  • 4

    Clinical evidence supports SGLT2 inhibitors in heart failure, while data on ischemic heart disease and arrhythmias remain promising but less definitive.

  • 5

    Safety considerations for SGLT2 inhibitors include risks of infections, volume depletion, and renal function changes, necessitating individualized care.

Original Source(s)

Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations

  • by Ziyun Wang, Yijin Wang, Wangning Shangguan, Tao Li

  • June 9, 2026

Related Content

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants

Soluble fms-like tyrosine kinase-1 and peripartum cardiomyopathy: an exploratory meta-analysis of association and diagnostic performance

Conduction system pacing compared with biventricular pacing for cardiac resynchronization therapy: a systematic review and meta-analysis